P Omede
Overview
Explore the profile of P Omede including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
429
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muccio V, Saraci E, Gilestro M, Oddolo D, Ruggeri M, Caltagirone S, et al.
Int J Lab Hematol
. 2017 Oct;
40(2):152-158.
PMID: 28984084
Introduction: Flow cytometry is a useful tool for diagnosis and minimal residual disease (MRD) study of hematological diseases. Standard sample preparation protocols are characterized by stain-lyse-wash (SLW). To prevent nonspecific...
2.
Lia G, Brunello L, Bruno S, Carpanetto A, Omede P, Festuccia M, et al.
Leukemia
. 2017 Aug;
32(3):765-773.
PMID: 28852198
Acute graft-vs-host disease (GVHD) is a serious complication after allografting. We carried out an exploratory study to investigate a potential correlation of surface antigens on extracellular vesicles (EVs) and acute...
3.
Gay F, Oliva S, Petrucci M, Montefusco V, Conticello C, Musto P, et al.
Leukemia
. 2016 Dec;
31(8):1727-1734.
PMID: 28008174
In newly diagnosed myeloma patients, upfront autologous transplant (ASCT) prolongs progression-free survival 1 (PFS1) compared with chemotherapy plus lenalidomide (CC+R). Salvage ASCT at first relapse may still effectively rescue patients...
4.
Larocca A, Bringhen S, Petrucci M, Oliva S, Falcone A, Caravita T, et al.
Leukemia
. 2016 Feb;
30(6):1320-6.
PMID: 26898189
This phase 2 trial evaluated three low-dose intensity subcutaneous bortezomib-based treatments in patients ⩾75 years with newly diagnosed multiple myeloma (MM). Patients received subcutaneous bortezomib plus oral prednisone (VP, N=51)...
5.
Ladetto M, Ferrero S, Drandi D, Festuccia M, Patriarca F, Mordini N, et al.
Leukemia
. 2015 Oct;
30(5):1211-4.
PMID: 26437784
No abstract available.
6.
Palma B, Guasco D, Pedrazzoni M, Bolzoni M, Accardi F, Costa F, et al.
Leukemia
. 2015 Oct;
30(2):409-16.
PMID: 26419509
The relationship between bone marrow (BM) cytokine and chemokine levels, cytogenetic profiles and skeletal involvement in multiple myeloma (MM) patients is not yet defined. This study investigated a cohort of...
7.
Giaccone L, Brunello L, Festuccia M, Gilestro M, Maffini E, Ferrando F, et al.
Bone Marrow Transplant
. 2015 Feb;
50(4):511-6.
PMID: 25665043
Immunophenotypic remission (IR) is a strong prognostic factor in myeloma patients. The combination of IR and conventional CR was retrospectively evaluated in 66 patients after allografting. IR was defined as...
8.
Rocci A, Hofmeister C, Geyer S, Stiff A, Gambella M, Cascione L, et al.
Leukemia
. 2014 May;
28(9):1922-6.
PMID: 24813918
No abstract available.
9.
DAscenzo F, Bollati M, Quadri G, Gonella A, Di Cuia M, De Simone V, et al.
Minerva Cardioangiol
. 2013 Nov;
61(6):675-81.
PMID: 24253459
Aim: Many randomized trials have compared coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) in terms of efficacy, but data comparing outcomes of patients in which these two...
10.
Musto P, Simeon V, Martorelli M, Petrucci M, Cascavilla N, Di Raimondo F, et al.
Leukemia
. 2013 Aug;
28(1):222-5.
PMID: 23958922
No abstract available.